Inhibits the proliferation and invasion of prostate cancer cells by the AR/SREBP1/FASN or API3K/Akt/SREBP1/FASN signaling pathways according to whether AR is positive or not (Wen et al., 2016). Here, AKT1 is linked to prostate cancer.